alfapump® – US FDA approval anticipated Q1 2025 and US launch planned for H2 2025; Strong progress with US reimbursement – CPT III codes issued & NTAP Application filed DSR® – Publication of RED DESERT and SAHARA data in peer-reviewed “European Journal of Heart Failure” highlights potential as treatment for Cardiorenal Syndrome; Positive data from...Read More